Pharmaceutical Hot Melt Extrusion Equipment Strategic Research Report 2025-2030, Featuring Baker Perkins, Coperion, Leistritz, Milacron, Thermo Fisher Scientific, Xtrutech - ResearchAndMarkets.com
The "Pharmaceutical Hot Melt Extrusion Equipment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The global market for Pharmaceutical Hot Melt Extrusion Equipment was valued at US$34.7 Million in 2024 and is projected to reach US$44.8 Million by 2030, growing at a CAGR of 4.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Pharmaceutical Hot Melt Extrusion Equipment market.
The pharmaceutical industry is increasingly adopting HME technology as it enables the production of a wide range of dosage forms, including tablets, granules, films, and transdermal patches, without the need for solvents or complex downstream processing steps. The continuous nature of the HME process also supports the development of more efficient and scalable manufacturing operations, reducing production time and costs.
What Factors Are Driving the Growth of the Global Pharmaceutical Hot Melt Extrusion Equipment Market?
The growth in the global pharmaceutical hot melt extrusion (HME) equipment market is driven by several factors, including the increasing demand for novel drug formulations, the rise in the number of poorly soluble drug candidates, and the ongoing advancements in pharmaceutical manufacturing technologies. One of the primary growth drivers is the growing need for solubility enhancement solutions to address the formulation challenges associated with poorly soluble APIs. As a significant proportion of new drug candidates discovered through modern drug development processes exhibit low solubility and bioavailability, pharmaceutical companies are seeking advanced formulation techniques such as HME to improve drug performance and therapeutic outcomes. HME's ability to produce amorphous solid dispersions and enhance the solubility of APIs is making it a critical tool in drug formulation, driving the demand for HME equipment.
The rise in the number of complex and targeted drug therapies, such as combination therapies and personalized medicine, is another key factor contributing to market growth. The development of these therapies requires advanced drug delivery systems that can achieve specific release profiles and deliver multiple APIs within a single dosage form. HME technology provides the flexibility and precision needed to create complex drug formulations with tailored release characteristics, supporting the development of innovative therapies that address unmet medical needs. The growing focus on personalized medicine, which involves tailoring treatments based on individual patient profiles, is driving the demand for HME equipment that can produce customized drug products with high precision and reproducibility.
Ongoing advancements in pharmaceutical manufacturing technologies are further supporting the growth of the HME equipment market. The adoption of continuous manufacturing, which integrates multiple processes into a single, streamlined production line, is gaining momentum in the pharmaceutical industry. HME equipment, with its continuous nature and ability to perform multiple processes within a single system, is a key enabler of continuous manufacturing. The use of HME in continuous production lines reduces production time, minimizes waste, and improves product quality, making it an attractive option for pharmaceutical manufacturers looking to enhance their operational efficiency. The integration of advanced control systems and automation technologies in HME equipment is further improving process control and product consistency, supporting the growth of the market.
Moreover, the increasing adoption of HME technology in the production of solid dispersions and controlled-release formulations is expanding the application scope of HME equipment. Solid dispersions are widely used to improve the dissolution rate and bioavailability of poorly soluble drugs, while controlled-release formulations provide sustained drug release over extended periods. HME's ability to produce these formulations with high precision and efficiency is driving its adoption in a wide range of therapeutic areas, including oncology, neurology, and pain management. The use of HME in developing abuse-deterrent formulations for controlled substances is also gaining traction, as it helps mitigate the risk of misuse and abuse of prescription drugs.
Additionally, the growing investment in pharmaceutical research and development (R&D) and the expansion of drug development pipelines are creating new opportunities for the HME equipment market. Pharmaceutical companies are investing in R&D to discover and develop new therapies for chronic and complex diseases, leading to an increase in the number of drug candidates that require advanced formulation techniques. The growing number of R&D projects focused on solubility enhancement, controlled-release formulations, and combination therapies is driving demand for HME equipment that supports these initiatives. The expansion of R&D activities in emerging markets such as Asia-Pacific and Latin America is further boosting demand for HME equipment, as these regions become hubs for pharmaceutical innovation and manufacturing.
Furthermore, the impact of the COVID-19 pandemic has highlighted the importance of advanced manufacturing technologies in ensuring the availability and supply of essential medicines. The increased focus on developing novel therapies and vaccines during the pandemic has underscored the need for efficient and scalable manufacturing solutions. The adoption of HME technology, with its ability to produce complex formulations and support continuous manufacturing, is playing a critical role in meeting the growing demand for innovative drug products. As these factors converge, the global pharmaceutical hot melt extrusion equipment market is poised for robust growth, driven by technological advancements, expanding pharmaceutical development activities, and the increasing emphasis on developing innovative and patient-centric drug formulations across various therapeutic areas.
Report Scope
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Baker Perkins Ltd., Coperion GmbH, Leistritz AG, Milacron Holdings Corp., Thermo Fisher Scientific, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Twin Screw Extruders segment, which is expected to reach US$28.0 Million by 2030 with a CAGR of a 4.1%. The Single Screw Extruder segment is also set to grow at 4.6% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $9.1 Million in 2024, and China, forecasted to grow at an impressive 6.5% CAGR to reach $9.5 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Segments
- End-Use (Research Laboratory, CMO, Pharma Companies)
- Product (Twin Screw Extruders, Single Screw Extruder, Laboratory Extruder, RAM Extruder)
Tariff Impact Analysis: Key Insights for 2025
What's Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Key Attributes:
Report Attribute | Details |
No. of Pages | 193 |
Forecast Period | 2024 - 2030 |
Estimated Market Value (USD) in 2024 | $34.7 Million |
Forecasted Market Value (USD) by 2030 | $44.8 Million |
Compound Annual Growth Rate | 4.3% |
Regions Covered | Global |
Key Topics Covered:
MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- Pharmaceutical Hot Melt Extrusion Equipment - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
MARKET TRENDS & DRIVERS
- Rising Demand for Solid Oral Dosage Forms Propels Growth in Pharmaceutical Hot Melt Extrusion Equipment Market
- Increasing Adoption of Hot Melt Extrusion (HME) in Drug Solubility and Bioavailability Enhancement Expands Addressable Market
- Technological Innovations in Twin-Screw and Continuous Extruders Strengthen Business Case for Market Growth
- Case Overview: Growth in Use of Hot Melt Extrusion in Sustained and Controlled Release Formulations Bodes Well for Market Expansion
- Rising Focus on Reducing Drug Development Time and Costs Drives Demand for HME Equipment
- Case Overview: Growth in Adoption of HME in Pediatric and Geriatric Drug Formulations Expands Market Reach
- Case Overview: Growth in Adoption of HME in Veterinary and Animal Health Products Expands Market Reach
FOCUS ON SELECT PLAYERS: Some of the 44 companies featured in this report
- Baker Perkins Ltd.
- Coperion GmbH
- Leistritz AG
- Milacron Holdings Corp.
- Thermo Fisher Scientific, Inc.
- Xtrutech Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/6pr50i
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250609423334/en/
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
